GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » EV-to-EBIT

WAVE Life Sciences (STU:1U5) EV-to-EBIT : -12.53 (As of Dec. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, WAVE Life Sciences's Enterprise Value is €1,740.55 Mil. WAVE Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-138.93 Mil. Therefore, WAVE Life Sciences's EV-to-EBIT for today is -12.53.

The historical rank and industry rank for WAVE Life Sciences's EV-to-EBIT or its related term are showing as below:

STU:1U5' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.8   Med: -3.94   Max: 0.07
Current: -12.05

During the past 11 years, the highest EV-to-EBIT of WAVE Life Sciences was 0.07. The lowest was -18.80. And the median was -3.94.

STU:1U5's EV-to-EBIT is ranked worse than
100% of 420 companies
in the Biotechnology industry
Industry Median: 10.01 vs STU:1U5: -12.05

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. WAVE Life Sciences's Enterprise Value for the quarter that ended in Sep. 2024 was €827.58 Mil. WAVE Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-138.93 Mil. WAVE Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -16.79%.


WAVE Life Sciences EV-to-EBIT Historical Data

The historical data trend for WAVE Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences EV-to-EBIT Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -1.49 -0.53 -3.43 -6.38

WAVE Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.99 -6.38 -8.37 -5.81 -6.14

Competitive Comparison of WAVE Life Sciences's EV-to-EBIT

For the Biotechnology subindustry, WAVE Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's EV-to-EBIT falls into.



WAVE Life Sciences EV-to-EBIT Calculation

WAVE Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1740.549/-138.931
=-12.53

WAVE Life Sciences's current Enterprise Value is €1,740.55 Mil.
WAVE Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-138.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences  (STU:1U5) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

WAVE Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=-138.931/827.5849
=-16.79 %

WAVE Life Sciences's Enterprise Value for the quarter that ended in Sep. 2024 was €827.58 Mil.
WAVE Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-138.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines